Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.57 |
| ▸ | JAK2 | O60674 | 5/20 | 0.57 |
| ▸ | JAK1 | P23458 | 4/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.38 |
| ▸ | SCN1A | P35498 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CD4 | P01730 | 2/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28407748 | 1.00 | JAK3 (0.57) | JAK3JAK2JAK1TYK2HTR6 | |
| SCHEMBL1376989 | 1.00 | JAK3 (0.57) | JAK3JAK2JAK1TYK2HTR6 | |
| SCHEMBL1374052 | 1.00 | JAK3 (0.57) | JAK3JAK2JAK1TYK2HTR6 | |
| SCHEMBL13693112 | 0.95 | JAK3 (0.60) | JAK3JAK2JAK1TYK2HTR6 | |
| SCHEMBL12148936 | 0.89 | JAK3 (0.42) | JAK3JAK2JAK1TYK2HTR6 | |
| SCHEMBL17711593 | 0.88 | JAK3 (0.62) | JAK3JAK2JAK1TYK2SMN1; SMN2 | |
| SCHEMBL19757371 | 0.88 | HTR6 (0.47) | JAK3JAK2JAK1TYK2HTR6 | |
| SCHEMBL17527473 | 0.86 | HTR6 (0.47) | JAK3JAK2JAK1TYK2HTR6 | |
| SCHEMBL17527471 | 0.86 | HTR6 (0.47) | JAK3JAK2JAK1TYK2HTR6 | |
| SCHEMBL24755055 | 0.84 | JAK3 (0.61) | JAK3JAK2JAK1TYK2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111265668-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| US-20220153743-A1 | PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | INTAS PHARMACEUTICALS LTD. (IN) | 2022-05-19 | — | — | US | disclosed |
| WO-2020183295-A1 | PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | INTAS PHARMACEUTICALS LTD. (IN) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153743-A1 | PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.